Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -23.39% is 97% above its 5-year average of -675.99%, near the high end of its 5-year range (-1945.60%–-9.49%).
91.29% above its 12-month average of -268.57%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -316.38%.
EBITDA MARGIN
-23.39%
EBITDA MARGIN AVG TTM
-268.57%
EBITDA MARGIN AVG 3Y
-492.64%
EBITDA MARGIN AVG 5Y
-675.99%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+91.29%
CURRENT VS 3Y AVG
+95.25%
CURRENT VS 5Y AVG
+96.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.11M
EBITDA Margin
-23.39%
TTM Avg
-268.57%
3Y Avg
-492.64%
5Y Avg
-675.99%
Market Cap
$14.11M
EBITDA Margin
-855.47%
TTM Avg
-475.86%
3Y Avg
-335.10%
5Y Avg
-307.83%
Market Cap
$13.73M
EBITDA Margin
-988.11%
TTM Avg
-1002.20%
3Y Avg
-1043.90%
5Y Avg
-1194.77%
Market Cap
$13.48M
EBITDA Margin
-839.37%
TTM Avg
-1027.77%
3Y Avg
-3215.79%
5Y Avg
-3215.79%
Market Cap
$15.03M
EBITDA Margin
-29916.57%
TTM Avg
-29916.57%
3Y Avg
-29916.57%
5Y Avg
-29916.57%
Market Cap
$13.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.24M
EBITDA Margin
-468.17%
TTM Avg
-602.06%
3Y Avg
-602.06%
5Y Avg
-23374.02%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.11M | -23.39% | -268.57% | -492.64% | -675.99% |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | -855.47% | -475.86% | -335.10% | -307.83% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.81M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.73M | -988.11% | -1002.20% | -1043.90% | -1194.77% |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.03M | -29916.57% | -29916.57% | -29916.57% | -29916.57% |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.37M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.24M | -468.17% | -602.06% | -602.06% | -23374.02% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.96M | -61.90% | -71.95% | -80.60% | -87.82% |
Gross Margin
84.2%
EBITDA Margin
-23.4%
Operating Margin
-30.4%
Net Margin
-39.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -316.38% |
| 2025-12-31 | -9.49% |
| 2025-06-30 | -479.85% |
| 2024-12-31 | -389.53% |
| 2024-06-30 | -429.31% |
| 2023-12-31 | -667.30% |
| 2023-06-30 | -1156.63% |
| 2022-12-31 | -358.02% |
| 2022-06-30 | -542.59% |
| 2021-12-31 | -1141.16% |
| 2021-06-30 | -1945.60% |
